A Study of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia (DREAM)
A Double-blind, Crossover, Placebo-controlled Study to Compare the Effects of Nighttime Administration of Suvorexant in Patients With Multiple Sclerosis Fatigue and Insomnia
Sponsor: Merck Sharp & Dohme LLC
Listed as NCT03110315, this PHASE4 trial focuses on Fatigue and Insomnia and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 11 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Mar 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Mar 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jun 2022 — Jul 2024 [monthly]
Completed PHASE4
-
May 2022 — Jun 2022 [monthly]
Completed PHASE4
Status: Recruiting → Completed
▶ Show 6 earlier versions
-
May 2021 — May 2022 [monthly]
Recruiting PHASE4
-
Jan 2021 — May 2021 [monthly]
Recruiting PHASE4
-
May 2019 — Jan 2021 [monthly]
Recruiting PHASE4
-
Jul 2018 — May 2019 [monthly]
Recruiting PHASE4
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE4
-
May 2017 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
Mar 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
- Theodore R. Brown, MD MPH
For direct contact, visit the study record on ClinicalTrials.gov .